Exec-Edge – Page 13 – ExecEdge

March Biosciences CAR-T Therapy Expectations and Phase 1 Experience

March Biosciences CAR-T Therapy Expectations and Phase 1 Experience

By Daniella Parra March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said. The company said the therapy employs a proprietary CAR design that enables selective targeting of...

Input your search keywords and press Enter.